AutoGenomics IPO Will Support Trial Of HPV Test On Infiniti Analyzer
This article was originally published in The Gray Sheet
Executive Summary
AutoGenomics is seeking to fund a clinical study of its HPV-QUAD human papillomavirus screening test through an initial public stock offering worth up to $86.3 million (see chart: "1AutoGenomics IPO")
You may also be interested in...
Financings In Brief
Molecular diagnostics firm AutoGenomics seeks to raise up to $65 million in an initial public offering. IlluminOss raises $28 mil. for fracture repair device. LoneStar Heart gets $20 million for heart failure implant. More financings.
Hologic Gains HPV Test Technology In $580 Million Third Wave Purchase
Hologic's purchase of molecular diagnostics firm Third Wave Technologies for $580 million provides a platform for near-term entry into the expanding, $200 million U.S. market for human papillomavirus testing
Prestige Expands UK Eye Care Range In Response To Consumer Demand
A “great consumer response” to TheraTears in the UK leads Prestige Consumer Healthcare to add TheraTears 5-in-1 Irritation and Redness eye drops to the range.